HASSELT, Belgium, March 26, 2014 /PRNewswire/ --
Complix, a biopharmaceutical company focused on the discovery and development of Cell Penetrating Alphabodies™ (CPABs), a unique class of protein therapeutics that are active against intracellular disease targets, announces that its CEO Dr Mark Vaeck will present tomorrow at BioCapital Europe 2014 in Amsterdam, the Netherlands (March 27th). Details of the presentation are listed below.
Help employers find you! Check out all the jobs and post your resume.
